| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 22043 |
| Drug | Polatuzumab vedotin |
| Brand | Polivy® |
| Indication | In combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) is indicated for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL). |
| Assessment Process | |
| Rapid review commissioned | 27/06/2022 |
| Rapid review completed | 27/07/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pola-R-CHP compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 31/08/2022 |
| Pre-submission consultation with Applicant | 08/11/2022 |
| Full submission received from Applicant | 26/01/2023 |
| Preliminary review sent to Applicant | 20/07/2023 |
| NCPE assessment re-commenced | 18/08/2023 |
| Factual accuracy sent to Applicant | 16/11/2023 |
| NCPE assessment re-commenced | 23/11/2023 |
| NCPE assessment completed | 05/12/2023 |
| NCPE assessment outcome | The NCPE recommends that polatuzumab vedotin (Polivy®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified
in the Health (Pricing and Supply of Medical Goods) Act 2013.
